tiprankstipranks
Trending News
More News >
Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
US Market
Advertisement

Alterity Therapeutics (ATHE) AI Stock Analysis

Compare
291 Followers

Top Page

ATHE

Alterity Therapeutics

(NASDAQ:ATHE)

Rating:50Neutral
Price Target:
$5.00
▼(-3.10%Downside)
Alterity Therapeutics has notable financial challenges, including declining revenues and persistent losses, which significantly impact its overall score. The technical analysis shows some positive momentum, but valuation metrics reflect the company's unprofitability. The lack of earnings call data and corporate events limits the assessment to available financial and technical data.
Positive Factors
Clinical Trial Results
Alterity Therapeutics reported positive clinical results for its Phase 2 trial of ATH434 in Multiple System Atrophy, including 48% slowing of clinical progression at the 50 mg dose level.
Financial Position
The balance sheet of Alterity Therapeutics has been strengthened, providing up to A$40M in additional funding which could extend the cash runway through CY26.
Market Potential
Based on the Phase 2 results, Alterity intends to engage the FDA to discuss next steps in the development of ATH434 in MSA, a disease with a small patient population but few treatment options.
Negative Factors
Market Sentiment
The recommendation on ATHE shares is being lowered, indicating potential concerns about future stock performance.
Stock Recommendation
The recommendation on ATHE shares is being lowered to Hold as these shares have exceeded the $4 price target.

Alterity Therapeutics (ATHE) vs. SPDR S&P 500 ETF (SPY)

Alterity Therapeutics Business Overview & Revenue Model

Company DescriptionAlterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
How the Company Makes MoneyAlterity Therapeutics makes money through a combination of research and development collaborations, licensing agreements, and potential sales of its proprietary drug candidates. Revenue is primarily generated through milestone payments and royalties from its partnerships with larger pharmaceutical companies. These partnerships are crucial as they provide financial support for the costly process of drug development and clinical trials. Additionally, Alterity may receive government grants or funding from non-profit organizations dedicated to advancing neurological research. The company's earnings are significantly influenced by the success of clinical trials and the subsequent approval and commercialization of its therapies.

Alterity Therapeutics Financial Statement Overview

Summary
Alterity Therapeutics faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. Despite a strong gross margin, profitability is severely impacted by high operating costs. The company maintains low leverage, but declining equity suggests ongoing financial strain.
Income Statement
45
Neutral
Alterity Therapeutics shows a declining revenue trend with revenue decreasing over the past year. The company has consistently faced operating losses, reflected in negative EBIT and net income margins. Gross profit margins remain positive, indicating some control over cost of goods sold, but overall profitability is hampered by high operating expenses.
Balance Sheet
50
Neutral
The balance sheet reveals a low debt-to-equity ratio, suggesting a conservative approach to leverage. However, the equity ratio has declined, indicating a reduction in shareholder equity relative to assets. Return on equity remains negative due to persistent losses, highlighting a challenge in delivering shareholder value.
Cash Flow
40
Negative
The cash flow statements depict negative free cash flows, indicating cash outflows in operations have not been offset by sufficient inflows. The operating cash flow to net income ratio suggests inefficiencies in converting income into cash. While financing activities have provided liquidity, reliance on external financing could pose risks.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue4.02M3.92M5.12M4.34M0.00
Gross Profit3.80M3.63M4.76M3.98M-112.43K
EBITDA-19.57M-17.51M-17.39M-19.36M-13.34M
Net Income-19.12M-13.81M-12.85M-15.31M-9.70M
Balance Sheet
Total Assets19.22M27.32M41.36M33.59M13.30M
Cash, Cash Equivalents and Short-Term Investments12.64M15.77M34.81M28.12M9.20M
Total Debt159.04K210.38K117.49K65.65K33.75K
Total Liabilities5.43M4.50M5.89M3.12M2.76M
Stockholders Equity13.80M22.81M35.47M30.47M10.55M
Cash Flow
Free Cash Flow-12.61M-20.04M-12.43M-17.34M-9.45M
Operating Cash Flow-12.61M-20.04M-12.34M-17.33M-9.43M
Investing Cash Flow-5.72K-36.46K-89.15K-10.47K-16.74K
Financing Cash Flow9.22M124.34K16.30M36.69M3.98M

Alterity Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.16
Price Trends
50DMA
4.36
Positive
100DMA
3.94
Positive
200DMA
3.18
Positive
Market Momentum
MACD
0.18
Negative
RSI
65.94
Neutral
STOCH
70.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATHE, the sentiment is Positive. The current price of 5.16 is above the 20-day moving average (MA) of 4.31, above the 50-day MA of 4.36, and above the 200-day MA of 3.18, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 65.94 is Neutral, neither overbought nor oversold. The STOCH value of 70.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATHE.

Alterity Therapeutics Risk Analysis

Alterity Therapeutics disclosed 44 risk factors in its most recent earnings report. Alterity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Alterity Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.46B-0.04-63.82%2.49%16.43%<0.01%
50
Neutral
$78.54M-154.88%20.25%
49
Neutral
$131.74M-58.89%
44
Neutral
$51.22M-1131.02%23.55%
41
Neutral
$59.84M-30.49%-100.00%37.59%
27
Underperform
$151.86M-102.48%-7.78%
$79.45M-111.42%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ATHE
Alterity Therapeutics
5.16
3.56
222.50%
CNTB
Connect Biopharma Holdings
2.27
0.92
68.15%
IKNA
Ikena Oncology
1.24
-0.43
-25.75%
IMRX
Immuneering
4.10
2.95
256.52%
IMMX
Immix Biopharma
2.90
0.84
40.78%
MAIA
MAIA Biotechnology, Inc.
1.71
-1.82
-51.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025